Rolf K. Hoffmann
Director/Board Member chez SUN PHARMACEUTICAL INDUSTRIES LTD.
Fortune : 1 M $ au 31/03/2024
Profil
Rolf K.
Hoffmann is currently the Chairman of BPC Plasma, Inc. He is also an Independent Director at Sun Pharmaceutical Industries Ltd.
and Genmab A.
In addition, he holds director positions at IDT Biologika GmbH, World Anti-Doping Agency, NavBio AG, Trizell Ltd., Idt Biologika Corp., Semdor Pharma Group GmbH, and Dessau-Rosslau.
Previously, he served as the Chief Executive Officer-Global Marketing at Lilly Deutschland GmbH and held various director and chairman positions at Biotest AG, EUSA Pharma, Inc., Trigemina, Inc., Copenhagen Capital A, Paratek Pharmaceuticals, Inc., Shield Therapeutics Plc, Ferring Holding, Inc., and Trizell Holding SA. He was also the Vice President-US Commercial Operations at Amgen, Inc. and the General Manager-Germany at Eli Lilly & Co. He has a graduate degree from Universität zu Köln, an MBA from The University of North Carolina at Chapel Hill, and a graduate degree from Deutsche Sporthochschule Köln.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GENMAB A/S
0,01% | 14/02/2024 | 3 363 ( 0,01% ) | 1 M $ | 31/03/2024 |
Postes actifs de Rolf K. Hoffmann
| Sociétés | Poste | Début |
|---|---|---|
| GENMAB A/S | Director/Board Member | 01/01/2016 |
| SUN PHARMACEUTICAL INDUSTRIES LTD. | Director/Board Member | 15/06/2023 |
| Dessau-Rosslau | Director/Board Member | - |
Semdor Pharma Group GmbH
 Semdor Pharma Group GmbH Pharmaceuticals: MajorHealth Technology Semdor Pharma Group GmbH is a German pharmaceutical company that specializes in narcotics and medical cannabis. With the merger of Cannamedical Pharma and PS Pharma, it is the only full-service pharmaceutical narcotics company in Germany that has its own medical cannabis brand and sales team. Semdor Pharma Group is the leading pharmaceutical company for narcotics and medical cannabis in Germany. | Director/Board Member | - |
| Idt Biologika Corp. | Director/Board Member | - |
Trizell Ltd.
 Trizell Ltd. BiotechnologyHealth Technology Trizell Ltd. engages in research and experimental development on biotechnology. The company was founded on April 14, 1997 and is headquartered in Chinnor, the United Kingdom. | Director/Board Member | - |
BPC Plasma, Inc.
 BPC Plasma, Inc. Pharmaceuticals: MajorHealth Technology BPC Plasma, Inc. manufactures pharmaceutical products. It offers the hyper immunoglobulin Nabi-HB, a key product used in the prevention of hepatitis B. The company was established in 2007 and is headquartered in Boca Raton, FL. | Chairman | - |
| World Anti-Doping Agency | Director/Board Member | - |
NavBio AG
 NavBio AG Miscellaneous Commercial ServicesCommercial Services NavBio AG provides business and management consulting services. | Director/Board Member | - |
| ░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Anciens postes connus de Rolf K. Hoffmann
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Rolf K. Hoffmann
| Universität zu Köln | Graduate Degree |
| The University of North Carolina at Chapel Hill | Masters Business Admin |
| Deutsche Sporthochschule Köln | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 8 |
|---|---|
| AMGEN INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| COPENHAGEN CAPITAL A/S | Finance |
| SUN PHARMACEUTICAL INDUSTRIES LTD. | Health Technology |
| GENMAB A/S | Health Technology |
| BIOTEST AG | Health Technology |
| PARATEK PHARMACEUTICALS, INC. | Health Technology |
| SHIELD THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 16 |
|---|---|
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Health Technology |
Trigemina, Inc.
 Trigemina, Inc. Pharmaceuticals: MajorHealth Technology Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA. | Health Technology |
STADA Arzneimittel AG
 STADA Arzneimittel AG Pharmaceuticals: OtherHealth Technology STADA Arzneimittel AG engages in the provision of healthcare and pharmaceutical products. It operates through the following segments: Generics, Consumer Healthcare, and Specialty. The Generics segment produces and distributes generic drugs. The Consumer Healthcare segment includes products such as OTC drugs, nutritional supplements and certain consumer healthcare products such as disinfectants and sunscreen. The Specialty segment includes branded generics, specialty generics, and biosimilars. Its brands include Zoflora, Grippostad, Nizoral, and Shampoo & Ladival. The company was founded on March 14, 1895 and is headquartered in Bad Vilbel, Germany. | Health Technology |
BPC Plasma, Inc.
BPC Plasma, Inc. Pharmaceuticals: MajorHealth Technology BPC Plasma, Inc. manufactures pharmaceutical products. It offers the hyper immunoglobulin Nabi-HB, a key product used in the prevention of hepatitis B. The company was established in 2007 and is headquartered in Boca Raton, FL. | Health Technology |
Lilly Deutschland GmbH
 Lilly Deutschland GmbH Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Lilly Deutschland GmbH is a pharmaceutical company based in Bad Homburg, Germany. The German company manufactures pharmaceutical products. The private company was founded in 1960 by Eli Lilly. The CEO is Kadir Tepebasi. | Health Technology |
| Amgen (Europe) GmbH | |
EUSA Pharma (UK) Ltd.
 EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom. | Distribution Services |
Ferring Holding, Inc.
 Ferring Holding, Inc. Pharmaceuticals: MajorHealth Technology Part of Ferring Holding SA, Ferring Holding, Inc. is a private company that manufactures and sells pharmaceuticals. The company is based in Parsippany, NJ. | Health Technology |
NavBio AG
NavBio AG Miscellaneous Commercial ServicesCommercial Services NavBio AG provides business and management consulting services. | Commercial Services |
Trizell Ltd.
Trizell Ltd. BiotechnologyHealth Technology Trizell Ltd. engages in research and experimental development on biotechnology. The company was founded on April 14, 1997 and is headquartered in Chinnor, the United Kingdom. | Health Technology |
| Idt Biologika Corp. | |
Semdor Pharma Group GmbH
Semdor Pharma Group GmbH Pharmaceuticals: MajorHealth Technology Semdor Pharma Group GmbH is a German pharmaceutical company that specializes in narcotics and medical cannabis. With the merger of Cannamedical Pharma and PS Pharma, it is the only full-service pharmaceutical narcotics company in Germany that has its own medical cannabis brand and sales team. Semdor Pharma Group is the leading pharmaceutical company for narcotics and medical cannabis in Germany. | Health Technology |
| Trizell Holding SA | |
| Dessau-Rosslau | Finance |
IDT Biologika GmbH
 IDT Biologika GmbH Pharmaceuticals: MajorHealth Technology IDT Biologika GmbH manufactures and distributes vaccines and biopharmaceuticals for the protection of human and animal health. The firm offers development services and manufacturing facilities for clinical phase I to III as well as commercial supplies for viral and bacterial human and animal health vaccines. The company was founded on July 1, 1921 and is headquartered in Dessau-Rosslau, Germany. | Health Technology |
| World Anti-Doping Agency |
